1 Obesity and prostate cancer: weighing the evidence European Urology, May 3, 2013 Review Article
2 Concurrent chemoradiotherapy with low dose weekly gemcitabine in medically inoperable muscle-invasive bladder cancer patients Clinical and Translational Oncology, April 25, 2013
3 Men with prostate cancer make positive dietary changes following diagnosis and treatment Cancer Causes and Control, May 7, 2013
4 Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study Journal of Clinical Oncology, April 29, 2013
5 Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma Annals of Oncology, May 6, 2013
6 Tobacco use and external beam radiation therapy for prostate cancer: Influence on biochemical control and late toxicity Cancer, May 1, 2013
7 Accelerated hyperfractionated radiotherapy within trimodality therapy concepts for stage IIIA/B non-small cell lung cancer: Markedly higher rate of pathologic complete remissions than with conventional fractionation European Journal of Cancer, April 25, 2013
8 Long-term follow-up of a phase III study comparing radiotherapy with or without weekly oxaliplatin for locoregionally advanced nasopharyngeal carcinoma Annals of Oncology, May 14, 2013
9 Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients data The Lancet Oncology, May 15, 2013 Review Article
10 Obesity and outcomes in patients treated with chemoradiotherapy for esophageal carcinoma Diseases of the Esophagus, April 30, 2013
Sponsor
Register now to view all the MDLinx contents (FREE)!
Login
Sponsor
Stay current - Media Tool
♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦
♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦
Close
Sponsor